Societal impact assessment

Abundance Potential

Lower Antibiotic Use May Modestly Reduce Resistance-Linked Deaths, Study Estimates

Assessment takeaway

Unknown · insufficient evidence

The target is the modeled 10% reduction in antibiotic consumption across classes. Its conditional human-wellbeing potential is meaningful but bounded by the small share of total bacterial-disease mortality represented, causal uncertainty, model sensitivity, and access tradeoffs. The article provides relevant scientific capability evidence; affordability, distributional effects, and environmental consequences remain unknown. The assessment uses only the supplied article and bounded source excerpt; omitted source text remains unknown.

AI-generated · Not editor reviewedAssessed 2026-11-04Rubric abundance-potential-v1

This describes conditional potential, not a probability or measured outcome. Unknown values are not zero, and harms are not subtracted from the total.

Assessment scope

Development
A hypothetical 10% reduction in consumption across antibiotic classes, assessed through the study’s modeled counterfactual.
Baseline
The study’s modeled current antibiotic-use levels; bacterial-disease mortality is the denominator for the reported 0.50% comparison.
Population
People globally at risk of bacterial disease and AMR, assuming modeled country-level patterns are relevant to them.
Geography
Global; the underlying surveillance covered 114 countries from 2000 to 2018, with low- and middle-income settings underrepresented.
Target assumptions
The modeled mortality difference depends on population-level use-resistance associations being modifiable and on reducing use without substantially limiting clinically necessary treatment. The study does not establish causality or a universal policy effect.

Five dimensions

Human wellbeing
2/4 · Under the modeled 10% reduction, the estimate is 38,000 fewer AMR-attributable deaths annually, a meaningful but bounded potential benefit: it is a projection from observational associations and represents about 0.50% of estimated global bacterial-disease mortality. Sources: evidence-1106, evidence-1107
Affordability and access
Unknown · The evidence does not estimate prices, affordability, or how a reduction would change access to needed antibiotics. The article identifies access to effective treatment as a key tradeoff. Sources: evidence-1111
Reach and fairness
Unknown · The distribution of benefits and harms across groups is not established, and low-resource settings are underrepresented in the surveillance data. Sources: evidence-1109
Environment and resources
Unknown · The supplied evidence does not assess environmental effects or resource use.
Scientific capability
2/4 · The analysis provides a substantial but bounded global evidence base for studying use-resistance relationships, using more than 30 million isolates across 114 countries. Ecological data, inconsistent associations across pathogen-drug pairs, and lack of causal identification limit what it establishes. Sources: evidence-1104, evidence-1108

Evidence, confidence and timing

Evidence maturity

Finding: Early speculative. The finding combines observational associations with a modeled counterfactual; it does not demonstrate the effect of an implemented reduction in antibiotic use.

Societal benefit: Early speculative. The mortality benefit is conditional on a modeled scenario and has not been established as an outcome of a policy or intervention.

Confidence: Low. The estimate relies on ecological associations that do not establish causality, varies under alternative model assumptions, and draws on surveillance that underrepresents low-resource settings. The supplied source excerpt omits its middle sections, which remain unknown.

Conditional time horizon: Near (0–5 years). The study frames reductions as potentially achievable in the near term, but the cited mortality difference is conditional on the modeled reduction and does not establish an implementation timeline or realized effect.

Possible benefits

  • In the modeled counterfactual, 10% lower antibiotic consumption across classes is associated with 38,000 fewer annual AMR-attributable deaths globally; the estimate is modest relative to total bacterial-disease mortality. Sources: evidence-1106, evidence-1107
  • The analysis supplies quantitative estimates of population-level use-resistance relationships that may inform research and public-health assessments, while leaving causal mechanisms and local effects unresolved. Sources: evidence-1104, evidence-1108

Risks and possible harms

  • If reductions limit access to antibiotics needed to treat bacterial disease, harms from inadequate treatment could offset resistance-related benefits; the study does not quantify this tradeoff for a specific policy or setting. Affected groups: People needing treatment, including populations in settings where antibiotic access is limited. Sources: evidence-1111

Distribution and adoption

Who might be excluded

  • Low-resource settings are underrepresented in the surveillance evidence: the dataset included about 2.7 million isolates from low- and middle-income countries versus 27.4 million from high-income countries. This is an evidence gap, not evidence that those populations would be excluded from an intervention. Sources: evidence-1109

Adoption barriers

  • Country-level observational associations do not establish the effect of a particular policy or predict outcomes for individual patients or specific places. Sources: evidence-1104
  • A policy would need to account for differing bacterial-disease burdens and access to effective treatment; the study offers no universal prescription. Sources: evidence-1111

Assumptions and conditions that could change the assessment

  • The population-level associations between antibiotic consumption and resistance reflect a modifiable relationship, although the study does not establish causality. Sources: evidence-1104
  • A 10% reduction across classes can be achieved without materially reducing necessary treatment or worsening inadequate access. Sources: evidence-1111
  • The global model remains relevant despite uneven surveillance coverage and substantial underrepresentation of low-resource settings. Sources: evidence-1106, evidence-1109
  • Stronger causal or intervention evidence showing the mortality effect of specific reductions, alongside effects on treatment access, could change the wellbeing assessment and confidence. Sources: evidence-1104, evidence-1111
  • More representative surveillance and setting-specific estimates, especially from low-resource settings, could change the global estimate and the assessment of reach and fairness. Sources: evidence-1109
  • Evidence that a reduction materially worsens access to effective treatment or increases bacterial-disease harms would lower the assessed net wellbeing potential. Sources: evidence-1111

Citations

  1. evidence-1104 · Burden of bacterial antimicrobial resistance associated with modifiable human antibiotic consumption: An observational study · B; e; n; j; a; m; i; n; ; J; .; ; S; i; n; g; e; r · 10.1371/journal.pmed.1005140 · Captured publisher article text · Open source
  2. evidence-1106 · Burden of bacterial antimicrobial resistance associated with modifiable human antibiotic consumption: An observational study · B; e; n; j; a; m; i; n; ; J; .; ; S; i; n; g; e; r · 10.1371/journal.pmed.1005140 · Captured publisher article text · Open source
  3. evidence-1107 · Burden of bacterial antimicrobial resistance associated with modifiable human antibiotic consumption: An observational study · B; e; n; j; a; m; i; n; ; J; .; ; S; i; n; g; e; r · 10.1371/journal.pmed.1005140 · Captured publisher article text · Open source
  4. evidence-1108 · Burden of bacterial antimicrobial resistance associated with modifiable human antibiotic consumption: An observational study · B; e; n; j; a; m; i; n; ; J; .; ; S; i; n; g; e; r · 10.1371/journal.pmed.1005140 · Captured publisher article text · Open source
  5. evidence-1109 · Burden of bacterial antimicrobial resistance associated with modifiable human antibiotic consumption: An observational study · B; e; n; j; a; m; i; n; ; J; .; ; S; i; n; g; e; r · 10.1371/journal.pmed.1005140 · Captured publisher article text · Open source
  6. evidence-1110 · Burden of bacterial antimicrobial resistance associated with modifiable human antibiotic consumption: An observational study · B; e; n; j; a; m; i; n; ; J; .; ; S; i; n; g; e; r · 10.1371/journal.pmed.1005140 · Captured publisher article text · Open source
  7. evidence-1111 · Burden of bacterial antimicrobial resistance associated with modifiable human antibiotic consumption: An observational study · B; e; n; j; a; m; i; n; ; J; .; ; S; i; n; g; e; r · 10.1371/journal.pmed.1005140 · Captured publisher article text · Open source